Amanda L. Elchynski
YOU?
Author Swipe
View article: Clinical Pharmacogenetics Implementation Consortium Guideline for <scp> <i>NAT2</i> </scp> Genotype and Hydralazine Therapy
Clinical Pharmacogenetics Implementation Consortium Guideline for <span> <i>NAT2</i> </span> Genotype and Hydralazine Therapy Open
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically …
View article: Evaluation of antifungal prophylaxis in pediatric patients with acute lymphoblastic leukemia or acute myeloid leukemia
Evaluation of antifungal prophylaxis in pediatric patients with acute lymphoblastic leukemia or acute myeloid leukemia Open
View article: The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation Open
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual’s genotype in conjunction with other important clinical factors. Despite significant evidence of genetic…
View article: Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic
Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic Open
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel‐based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was in the …
View article: Multidisciplinary Consulting Team for Complicated Cases of Neurodevelopmental and Neurobehavioral Disorders: Assessing the Opportunities and Challenges of Integrating Pharmacogenomics into a Team Setting
Multidisciplinary Consulting Team for Complicated Cases of Neurodevelopmental and Neurobehavioral Disorders: Assessing the Opportunities and Challenges of Integrating Pharmacogenomics into a Team Setting Open
Neurodevelopmental disorders have steadily increased in incidence in the United States. Over the past decade, there have been significant changes in clinical diagnoses and treatments some of which are due to the increasing adoption of phar…
View article: Utilizing a Human–Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support
Utilizing a Human–Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support Open
A formal assessment of pharmacogenomics clinical decision support (PGx-CDS) by providers is lacking in the literature. The objective of this study was to evaluate the usability of PGx-CDS tools that have been implemented in a healthcare se…
View article: Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing Open
View article: Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease Open
View article: Genotype-Guided Hydralazine Therapy
Genotype-Guided Hydralazine Therapy Open
Background: Despite its approval in 1953, hydralazine hydrochloride continues to be used in the management of resistant hypertension, a condition frequently managed by nephrologists and other clinicians. Hydralazine hydrochlo…
View article: 662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections Open
Background Options for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections were historically limited to antibiotics with limited efficacy and significant toxicities. Ceftazidime/avibactam (CA) and meropenem/vaborbactam (M…